Bicycle Therapeutics vs Arcus Biosciences
BCYC and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCYC and RCUS compare
Arcus Biosciences is the larger company, worth 9.4 times as much as Bicycle Therapeutics ($2.2B against $236M).
Bicycle Therapeutics grew revenue faster over the last twelve months (195% versus −58.3% for Arcus Biosciences).
Bicycle Therapeutics keeps more of each dollar of sales as profit, with a net margin of −170% compared with −453% at Arcus Biosciences.
Bicycle Therapeutics scores higher on the StockData Score (11 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCYC | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $236M | $2.2B |
| Share price | $3.37 | $17.43 |
| Change, 1 year | −48.6% | −12.8% |
| Change, 5 years | −94.2% | −63.3% |
| Beta (5Y) | 1.37 | 1.42 |
| Employees | 288 | 601 |
| StockData Score | ||
| Total score | 11 (better) | 3 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.8× (better) | 22.2× |
| P/B | 0.5× (better) | 6.2× |
| FCF yield | −74.9% | −21.0% (better) |
| Fair value | $16.02 | $5.80 |
| Margin of safety | 79.0% (better) | −201% |
| Growth | ||
| Revenue growth (TTM) | 195% (better) | −58.3% |
| Revenue growth, 5Y average | 47.5% (better) | 25.9% |
| Profitability | ||
| Operating margin | −189% (better) | −475% |
| Net margin | −170% (better) | −453% |
| FCF margin | −212% (better) | −466% |
| Return on equity | −25.2% (better) | −114% |
| Return on invested capital | −4543% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −815.6× | −43.2× (better) |
| Current ratio | 12.09 (better) | 3.34 |
| Altman Z-score | 0.04 (better) | −1.35 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | – | −12.6% |
| Shareholder yield | 0.00% (better) | −12.6% |
| Ownership | ||
| Held by institutions | 53.4% | 96.3% |
| Held by insiders | 21.3% | 31.7% |
| Insider net buying, 12 months | −$523K (better) | −$9.3M |
| Short interest, % of float | – | 15.2% |
Go deeper
- BCYC stock overview
- BCYC income statement
- BCYC valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.